Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: February 4, 2020 (Event Date); Signed February 10, 2020
Context: The Company, an emerging growth company incorporated in Nevada, entered into a Material Definitive Agreement with The Amyotrophic Lateral Sclerosis (ALS) Association.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The primary financial data point disclosed is the value of a research grant.
- Grant Award Total: $500,000
- Payment Schedule:
- $300,000 in February 2020
- $100,000 in February 2021
- $100,000 in August 2021
- Cost Restrictions: Indirect costs or overhead allocations are capped at 10% of the award.
Material Changes
The filing discloses the execution of a Research Grant Agreement dated February 4, 2020. This agreement funds specific studies regarding the efficacy of the Company's candidate, XPro1595, in reversing ALS in vitro and protecting against ALS model phenotypes in vivo. The agreement has an initial term of 24 months.
Outlook, Risks, and Management Commentary
Management Commentary: The Company issued a press release on February 10, 2020, announcing the receipt of the award (Exhibit 99.1).
Contingencies: Future payments of $200,000 (due in 2021) are contingent upon the Company providing specific research progress reports and grant expenditure reports by the due dates outlined in the agreement.
Risks: The agreement includes customary representations, warranties, confidentiality provisions, and termination provisions. The Company is restricted from spending more than 10% of the award on indirect costs.
Investor Verification Checklist
- Verify the receipt of the initial $300,000 tranche in February 2020.
- Monitor the Company's ability to meet the reporting requirements necessary to secure the remaining $200,000 in 2021.
- Review the full text of the Award Agreement (Exhibit 10.1) for specific termination clauses and confidentiality obligations.
- Track the progress of the XPro1595 studies funded by this grant to assess potential future commercial viability.